Morten Persson
Copenhagen, 2200, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Journal: PET clinics
Published: March 08, 2017
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Journal: BMC cancer
Published: February 15, 2017
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Journal: Oncotarget
Published: August 26, 2016
Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 31, 2016
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.
Journal: Clinical and translational imaging
Published: May 24, 2016
Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Journal: PloS one
Published: August 24, 2015
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Journal: Theranostics
Published: June 15, 2015
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 01, 2015
C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.
Journal: Scientific reports
Published: April 10, 2015
Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.
Journal: The Journal of pathology
Published: March 05, 2015
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Journal: Molecular pharmaceutics
Published: June 24, 2014
Last Updated: 09/26/2026